Cited by 744Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 67 of the 70 references it cites were found in a registry or an index.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Open access

Bluemn, Eric G., Coleman, Ilsa M., Lucas, Jared M., Coleman, Roger T., Hernandez-Lopez, Susana, Tharakan, Robin, Bianchi-Frias, Daniella, Dumpit, Ruth F., Kaipainen, Arja, Corella, Alexandra N., Yang, Yu Chi, Nyquist, Michael D., Mostaghel, Elahe, Hsieh, Andrew C., Zhang, Xiaotun, Corey, Eva, Brown, Lisha G., Nguyen, Holly M., Pienta, Kenneth, Ittmann, Michael, Schweizer, Michael, True, Lawrence D., Wise, David, Rennie, Paul S., Vessella, Robert L., Morrissey, Colm, Nelson, Peter S.·2017·Cancer Cell

DOI 10.1016/j.ccell.2017.09.003PMC PMC5750052

Open this paper in CoChat — free account Open PDF

Abstract

Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC). Though highly effective, AR antagonism can produce tumors that bypass a functional requirement for AR, often through neuroendocrine (NE) transdifferentiation. Through the molecular assessment of mPCs over two decades, we find a phenotypic shift has occurred in mPC with the emergence of an AR-null NE-null phenotype. These "double-negative" PCs are notable for elevated FGF and MAPK pathway activity, which can bypass AR dependence. Pharmacological inhibitors of MAPK or FGFR repressed the growth of double-negative PCs in vitro and in vivo. Our results indicate that FGF/MAPK blockade may be particularly efficacious against mPCs with an AR-null phenotype.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2017.09.003

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
APE: analyses of phylogenetics and evolution in R language
Paradis, E., Claude, J., & Strimmer, K. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg412 · Cited by 11,335
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Software for Computing and Annotating Genomic Ranges
Lawrence, M. F., Huber, W. K., Pagès, H., Aboyoun, P., Carlson, M. R. J., Gentleman, R. C., Morgan, M. T., & Carey, V. J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003118 · Cited by 4,475
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Several drugs, including improved AR antagonists and inhibitors of androgen synthesis, extend survival (de Bono et al., 2011; Scher et al., 2012), although to date complete remissions have been rare.”
Background
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713

Show all 70 references

Sorted by citations

Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citation
Genetics and biology of prostate cancerPreprint
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 814
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, À., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 585
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W. T., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., Marzo, A. M. D., Nelson, P. S., & Yegnasubramanian, S. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 544
Self-citation
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
Labrecque, M. P., Coleman, I. M., Brown, L. G., True, L. D., Kollath, L. A., Lakely, B., Nguyen, H. M., Yang, Y. C., da Costa, R. M. G., Kaipainen, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128212 · Cited by 461
Self-citation
Biologically informed deep neural network for prostate cancer discovery
Elmarakeby, H. A., Hwang, J., Arafeh, R., Crowdis, J., Gang, S., Liu, D., AlDubayan, S. H., Salari, K., Kregel, S., Richter, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03922-4 · Cited by 456
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Beltran, H., Hruszkewycz, A. M., Scher, H. I., Hildesheim, J., Isaacs, J. S., Yu, E. Y., Kelly, K., Lin, D. W., Dicker, A. P., Arnold, J. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1423 · Cited by 426
Self-citation
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365
Self-citation
Patient derived organoids to model rare prostate cancer phenotypes
Puca, L., Bareja, R., Prandi, D., Shaw, R. C., Benelli, M., Karthaus, W. R., Hess, J., Sigouros, M., Donoghue, A., Kossaï, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04495-z · Cited by 366
Clinical features of neuroendocrine prostate cancer
Conteduca, V., Oromendia, C., Eng, K., Bareja, R., Sigouros, M., Molina, A. M., Faltas, B. M., Sboner, A., Mosquera, J. M., Elemento, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.011 · Cited by 358
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Chan, J. M., Zaidi, S., Love, J. R., Zhao, J. L., Setty, M. N., Wadosky, K. M., Gopalan, A., Choo, Z.-N., Persad, S., Choi, J., et al. (2022) · Science · doi:10.1126/science.abn0478 · Cited by 359
Clinical and Biological Features of Neuroendocrine Prostate Cancer
Yamada, Y., & Beltran, H. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01003-9 · Cited by 328
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Rice, M. A., Malhotra, S. V., & Stoyanova, T. I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 325
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
Ghoochani, A., Hsu, E., Aslan, M., Rice, M. A., Nguyen, H. M., Brooks, J. D., Corey, E., Paulmurugan, R., & Stoyanova, T. I. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3477 · Cited by 324
Self-citation
Spatially resolved clonal copy number alterations in benign and malignant tissue
Erickson, A. M., He, M., Berglund, E., Marklund, M., Mirzazadeh, R., Schultz, N., Kvastad, L., Andersson, A., Bergenstråhle, L., Bergenstråhle, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05023-2 · Cited by 315
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
Brady, L., Kriner, M., Coleman, I. M., Morrissey, C. M., Roudier, M. P., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 310
Self-citation
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
Nyquist, M. D., Corella, A. N., Coleman, I. M., Sarkar, N. D., Kaipainen, A., Ha, G., Gulati, R., Ang, L. S., Chatterjee, P., Lucas, J. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107669 · Cited by 297
Self-citation
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Beltran, H., Oromendia, C., Danila, D. C., Montgomery, B., Hoimes, C. J., Szmulewitz, R. Z., Vaishampayan, U. N., Armstrong, A. J., Stein, M. N., Pinski, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1912 · Cited by 301
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Tang, F., Xu, D., Wang, S., Wong, C. K., Martinez‐Fundichely, A., Lee, C. J., Cohen, S. M., Park, J., Hill, C. E., Eng, K. W., et al. (2022) · Science · doi:10.1126/science.abe1505 · Cited by 272
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 287
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 260
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 262
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression
Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.009 · Cited by 248
ONECUT2 is a driver of neuroendocrine prostate cancer
Guo, H., Ci, X., Ahmed, M., Hua, J. T., Soares, F., Lin, D., Puca, L., Vosoughi, A., Xue, H., Li, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08133-6 · Cited by 253
Towards precision oncology in advanced prostate cancer
Ku, S., Gleave, M. E., & Beltran, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0237-8 · Cited by 230
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0891 · Cited by 214
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z. A., & Katoh, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00869-z · Cited by 218
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Beltran, H., Romanel, A., Conteduca, V., Casiraghi, N. A., Sigouros, M., Franceschini, G. M., Orlando, F., Fedrizzi, T., Ku, S., Dann, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131041 · Cited by 196
N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
Berger, A., Brady, N. J., Bareja, R., Robinson, B., Conteduca, V., Augello, M. A., Puca, L., Ahmed, A., Dardenne, É., Lü, X., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127961 · Cited by 195
Molecular events in neuroendocrine prostate cancer development
Wang, Y., Wang, Y., Ci, X., Choi, S. Y. C., Crea, F., Lin, D., & Wang, Y. Z. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00490-0 · Cited by 195
2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
Blomme, A., Ford, C. A., Mui, E. J., Patel, R., Ntala, C., Jamieson, L. E., Planque, M., McGregor, G. H., Peixoto, P., Hervouet, É., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16126-7 · Cited by 184
Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells
Namekawa, T., Ikeda, K., Horie‐Inoue, K., & Inoue, S. (2019) · Cells · doi:10.3390/cells8010074 · Cited by 180
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Laere, B. D., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P., Oyen, P. V., Ghysel, C., Ampe, J., Ost, P., Demey, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1943 · Cited by 177
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer
Wang, H., Li, N., Liu, Q., Guo, J., Pan‐Hammarström, Q., Cheng, B., Xu, J., Dong, B., Yang, G., Yang, B., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.016 · Cited by 175
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Davies, A., Nouruzi, S., Ganguli, D., Namekawa, T., Thaper, D., Linder, S., Karaoğlanoğlu, F., Omur, M. E., Kim, S., Kobelev, M., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00743-5 · Cited by 170
Non-canonical functions of the RB protein in cancer
Dick, F. A., Goodrich, D. W., Sage, J., & Dyson, N. J. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0008-5 · Cited by 175
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen, S., Bossi, A., Davis, I. D., Bono, J. S. D., Fizazi, K. S., James, N. D., Mottet, N., Shore, N. D., Small, E. J., Smith, M. R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.018 · Cited by 174
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Baca, S. C., Takeda, D. Y., Seo, J.-H., Hwang, J. H., Ku, S., Arafeh, R., Arnoff, T. E., Agarwal, S., Bell, C. A., O’Connor, E. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22139-7 · Cited by 163
Self-citation
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Deng, S., Wang, C., Wang, Y., Xu, Y., Li, X., Johnson, N. A., Mukherji, A., Lo, U., Xu, L., Gonzalez, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00431-9 · Cited by 163
Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis
Adekoya, T. O., & Richardson, R. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124449 · Cited by 160
Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation
He, Y., Ji, Z., Gong, Y., Fan, L., Xu, P., Chen, X., Miao, J., Zhang, K., Zhang, W., Ma, P., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112033 · Cited by 160
Integrative epigenetic taxonomy of primary prostate cancer
Stelloo, S., Nevedomskaya, E., Kim, Y., Schuurman, K., Valle-Encinas, E., Lobo, J., Krijgsman, O., Peeper, D. S., Chang, S. L., Feng, F. Y.-C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07270-2 · Cited by 154
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
Davies, A., Zoubeidi, A., Beltran, H., & Selth, L. A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0225 · Cited by 170
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905384117 · Cited by 146
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 168
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
Lee, J. K., Bangayan, N. J., Chai, T., Smith, B. A., Pariva, T. E., Yun, S., Vashisht, A. A., Zhang, Q., Park, J. W., Corey, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802354115 · Cited by 148
Self-citation
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
Cyrta, J., Augspach, A., Filippo, M. R. D., Prandi, D., Thienger, P., Benelli, M., Cooley, V., Bareja, R., Wilkes, D. C., Chae, S.-S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19328-1 · Cited by 153
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05084-1 · Cited by 152
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Li, Q., Deng, Q., Chao, H., Liu, X., Lu, Y., Lin, K., Liu, B., Tang, G., Zhang, D., Tracz, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06067-7 · Cited by 137
Development and prevalence of castration-resistant prostate cancer subtypes
Vellky, J. E., & Ricke, W. A. (2020) · Neoplasia · doi:10.1016/j.neo.2020.09.002 · Cited by 152
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
Choudhury, A. D., Werner, L. L., Francini, E., Wei, X. X., Ha, G., Freeman, S. S., Rhoades, J., Reed, S. C., Gydush, G., Rotem, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122109 · Cited by 139
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance
Jamroze, A., Chatta, G. S., & Tang, D. G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.006 · Cited by 140
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, W. S., Coleman, I. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37874-2 · Cited by 138
Self-citation
Loss and revival of androgen receptor signaling in advanced prostate cancer
Formaggio, N., Rubin, M. A., & Theurillat, J.-P. P. (2021) · Oncogene · doi:10.1038/s41388-020-01598-0 · Cited by 141
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Doebley, A.-L., Ko, M., Liao, H., Cruikshank, A. E., Santos, K., Kikawa, C., Hiatt, J. B., Patton, R. D., Sarkar, N. D., Collier, K. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35076-w · Cited by 135
Self-citation
Biological Evolution of Castration-resistant Prostate Cancer
Davies, A., Conteduca, V., Zoubeidi, A., & Beltran, H. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.01.016 · Cited by 126
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Bergmann, L., Sailer, V., Lessel, D., Janzen, E., Greimeier, S., Kirfel, J., Perner, S., Pantel, K., Werner, S., & Amsberg, G. V. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02255-y · Cited by 123
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A. M., Preković, S., Wetterskog, D., Tolonen, T. T., Vuorinen, E. M., Kiviaho, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25624-1 · Cited by 123
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy
Lawrence, M. G., Obinata, D., Sandhu, S. K., Selth, L. A., Wong, S. Q., Porter, L. H., Lister, N. L., Pook, D. W., Pezaro, C. J., Goode, D. L., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.020 · Cited by 123
Concise Review: Prostate Cancer Stem Cells: Current Understanding
Skvortsov, S., Skvortsova, I., Tang, D. G., & Dubrovska, A. (2018) · Stem Cells · doi:10.1002/stem.2859 · Cited by 123
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Spratt, D. E., Alshalalfa, M., Fishbane, N., Weiner, A. B., Mehra, R., Mahal, B. A. V., Lehrer, J. M., Liu, Y., Zhao, S. G., Speers, C. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1587 · Cited by 122
NSD2 is a conserved driver of metastatic prostate cancer progression
Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 122
FGF/FGFR signaling pathway involved resistance in various cancer types.
Zhou, Y., Wu, C., Lu, G., Hu, Z., Chen, Q., & Du, X. (2020) · Journal of Cancer · doi:10.7150/jca.40531 · Cited by 117
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and TherapiesPreprint
Puca, L., Vlachostergios, P. J., & Beltran, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030593 · Cited by 120
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
Lissa, D., Takahashi, N., Desai, P. A., Manukyan, I., Schultz, C. W., Rajapakse, V. N., Velez, M. J., Mulford, D. A., Roper, N., Nichols, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29517-9 · Cited by 112
Molecular Subtypes of Prostate Cancer
Arora, K., & Barbieri, C. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0707-9 · Cited by 119
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression
Bolis, M., Bossi, D., Vallerga, A., Ceserani, V., Cavalli, M., Impellizzieri, D., Rito, L. D., Zoni, E., Mosole, S., Elia, A. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26840-5 · Cited by 124
Self-citation
A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer
Bai, S., Cao, S., Jin, L., Kobelski, M. M., Schouest, B., Wang, X., Ungerleider, N., Baddoo, M., Zhang, W., Corey, E., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0768-8 · Cited by 119
Self-citation
Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage
Chatterjee, P., Schweizer, M. T., Lucas, J. M., Coleman, I., Nyquist, M. D., Frank, S. B., Tharakan, R., Mostaghel, E. A., Luo, J., Pritchard, C. C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127613 · Cited by 107
Self-citation
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
Singh, N., Ramnarine, V. R., Song, J. H., Pandey, R., Padi, S. K. R., Nouri, M., Olive, V., Kobelev, M., Okumura, K., McCarthy, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26901-9 · Cited by 107
Future applications of FGF/FGFR inhibitors in cancer
Ghedini, G. C., Ronca, R., Presta, M., & Giacomini, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1491795 · Cited by 106
Heterogeneity in Cancer
MacDonald, W., Purcell, C., Pinho-Schwermann, M. P., Stubbs, N. M., Srinivasan, P. R., & El‐Deiry, W. S. (2025) · Cancers · doi:10.3390/cancers17030441 · Cited by 119
Prostate cancer-associated lncRNAs
Mitobe, Y., Takayama, K., Horie‐Inoue, K., & Inoue, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.012 · Cited by 108
Understanding and targeting prostate cancer cell heterogeneity and plasticity
Tang, D. G. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.001 · Cited by 102
The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
Davies, A., Zoubeidi, A., & Selth, L. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0420 · Cited by 100
LIN28B promotes the development of neuroendocrine prostate cancer
Lovnicki, J. M., Gan, Y., Feng, T., Li, Y., Xie, N., Ho, C.-H., Lee, A. R., Chen, X., Nappi, L., Han, B., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135373 · Cited by 100
Cancer Plasticity: The Role of mRNA Translation
Lee, L. J., Papadopoli, D. J., Jewer, M., Rincon, S. V. D., Topisirović, I., Lawrence, M. G., & Postovit, L.-M. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.005 · Cited by 104
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G. R., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S. Y. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1625 · Cited by 95
Therapy considerations in neuroendocrine prostate cancer: what next?
Beltran, H., & Demichelis, F. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0140 · Cited by 98
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V. M., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., THOMAS, G. V., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0134-5 · Cited by 96
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
He, Y., Wei, T., Ye, Z., Orme, J. J., Lin, D., Sheng, H., Fazli, L., Karnes, R. J., Jiménez, R. E., Wang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21860-7 · Cited by 94
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
Hawley, J. E., Obradović, A., Dallos, M. C., Lim, E. A., Runcie, K. D., Ager, C. R., McKiernan, J., Anderson, C. B., DeCastro, G. J., Weintraub, J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.006 · Cited by 93
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
Sayar, E., Patel, R. A., Coleman, I. M., Roudier, M. P., Zhang, A., Mustafi, P., Low, J., Hanratty, B. P., Ang, L. S., Bhatia, V., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.162907 · Cited by 95
Self-citation
The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance
Hepburn, A. C., Steele, R. E., Veeratterapillay, R., Wilson, L., Kounatidou, E. E., Barnard, A., Berry, P., Cassidy, J., Moad, M., El‐Sherif, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0712-y · Cited by 89
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Lundberg, A., Zhang, M., Aggarwal, R. R., Li, H., Zhang, L., Foye, A., Sjöström, M., Chou, J., Chang, K. C., Moreno-Rodriguez, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0593 · Cited by 86
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 84
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Bumbaca, B., & Li, W. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.007 · Cited by 83
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Smith, R. L., Liu, M., Liby, T. A., Bayani, N., Bucher, E., Chiotti, K., Derrick, D. S., Chauchereau, A., Heiser, L. M., Alumkal, J. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78798-x · Cited by 83
The FGF/FGFR system in the physiopathology of the prostate gland
Giacomini, A., Grillo, E., Rezzola, S., Ribatti, D., Rusnati, M., Ronca, R., & Presta, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00005.2020 · Cited by 81
Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for 18F-FDG Imaging of PSMA-Suppressed Tumors
Bakht, M. K., Lovnicki, J. M., Tubman, J., Stringer, K. F., Chiaramonte, J., Reynolds, M. R., Derecichei, I., Ferraiuolo, R., Fifield, B., Lubanska, D., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.231068 · Cited by 79
Self-citation
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Palanisamy, N., Yang, J., Shepherd, P. D. A., Li-Ning-Tapia, E. M., Labanca, E., Manyam, G. C., Ravoori, M. K., Kundra, V., Araujo, J. C., Efstathiou, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0479 · Cited by 78
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy
Wilkinson, S. C., Ye, H., Karzai, F. H., Harmon, S. A., Terrigino, N. T., VanderWeele, D. J., Bright, J. R., Atway, R., Trostel, S. Y., Carrabba, N. V., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.009 · Cited by 79
Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review
Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 80
MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer
Kalogirou, C., Linxweiler, J., Schmucker, P., Snaebjornsson, M. T., Schmitz, W., Wach, S., Krebs, M., Hartmann, E., Puhr, M., Müller, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25325-9 · Cited by 82
The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62
Linares, J. F., Cid-Diaz, T., Durán, Á., Osrodek, M., Martínez-Ordóñez, A., Reina‐Campos, M., Kuo, H., Elemento, O., Martin, M. L., Cordes, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110792 · Cited by 84
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
Geng, H., Xue, C., Mendonca, J., Sun, X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V. J., Chen, A. P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07411-7 · Cited by 79
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
Tiwari, R., Manzar, N., Bhatia, V., Yadav, A., Nengroo, M. A., Datta, D. B., Carskadon, S. L., Gupta, N., Sigouros, M., Khani, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14184-0 · Cited by 78
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis
Han, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 74

Authors: Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., Yang, Y. C., Nyquist, M. D., Mostaghel, E., Hsieh, A. C., Zhang, X., Corey, E., Brown, L. G., Nguyen, H. M., Pienta, K., Ittmann, M., Schweizer, M., True, L. D., Wise, D., Rennie, P. S., Vessella, R. L., Morrissey, C., & Nelson, P. S.
Affiliations: University of Washington (US)
Fred Hutch Cancer Center (US)
Johns Hopkins University (US)
Baylor College of Medicine (US)
Memorial Sloan Kettering Cancer Center (US)
Vancouver Prostate Centre (CA)
Corresponding author: Morrissey, Colm
Nelson, Peter S.
ORCID: Coleman, Ilsa M.
Lucas, Jared M.
Dumpit, Ruth F.
Kaipainen, Arja
Corella, Alexandra N.
Yang, Yu Chi
Nyquist, Michael D.
Mostaghel, Elahe
Hsieh, Andrew C.
Corey, Eva
Brown, Lisha G.
Nguyen, Holly M.
Pienta, Kenneth
Ittmann, Michael
Schweizer, Michael
True, Lawrence D.
Wise, David
Morrissey, Colm
Nelson, Peter S.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2017-10
Volume: 32
Issue: 4
Pages: 474-489.e6
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2017.09.003
PMC: PMC5750052
OpenAlex: W2762381618
Cited by: 744
References: 70
Citations by year: 2026: 73 · 2025: 96 · 2024: 96 · 2023: 102 · 2022: 84 · 2021: 96 · 2020: 73 · 2019: 69 · 2018: 53 · 2017: 2
FWCI: 44.57
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 373 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: NIH (P50CA097186, P01 CA163227)
DOD (PC140794, PC160662)
DF/HCC Mazzone
Institute for Prostate Cancer Research
Richard M. Lucas Foundation
Movember
Prostate Cancer Foundation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: androgen receptor signaling, prostate cancer, metastatic prostate cancer, FGF signaling, MAPK signaling, FGFR inhibitors, MAPK inhibitors, neuroendocrine transdifferentiation, treatment resistance
MeSH terms: Androgen Antagonists, Animals, Cell Differentiation, Fibroblast Growth Factors, Humans, Male, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Receptors, Fibroblast Growth Factor, MAP Kinase Signaling System, Cell Line, Tumor, Mice, Inhibitor of Differentiation Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks